Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Capital Expenditures: 2010-2024

Historic Capital Expenditures for OptimizeRx (OPRX) over the last 14 years, with FY2024 value amounting to $338000.0.

  • OptimizeRx's Capital Expenditures fell 1500.0% to $34000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year decrease of 5842.7%. This contributed to the annual value of $338000.0 for FY2024, which is 5688.78% down from last year.
  • OptimizeRx's Capital Expenditures amounted to $338000.0 in FY2024, which was down 5688.78% from $784000.0 recorded in FY2023.
  • OptimizeRx's Capital Expenditures' 5-year high stood at $784000.0 during FY2023, with a 5-year trough of $68041.0 in FY2020.
  • Over the past 5 years, OptimizeRx's median Capital Expenditures value was $338000.0 (recorded in 2024), while the average stood at $343553.4.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 43521.55% in 2021, then crashed by 5688.78% in 2024.
  • Over the past 5 years, OptimizeRx's Capital Expenditures (Annual) stood at $68041.0 in 2020, then skyrocketed by 435.22% to $364166.0 in 2021, then crashed by 55.09% to $163560.0 in 2022, then surged by 379.33% to $784000.0 in 2023, then plummeted by 56.89% to $338000.0 in 2024.
  • Its Capital Expenditures stands at $338000.0 for FY2024, versus $784000.0 for FY2023 and $163560.0 for FY2022.